Trials / Completed
CompletedNCT00436800
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective: To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma. Secondary objectives: To assess the toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent NPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | 1000mg/m² over 10mg/m²/min |
| DRUG | Oxaliplatin | 100 mg/m² over 2 hours. |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2007-02-19
- Last updated
- 2009-09-18
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT00436800. Inclusion in this directory is not an endorsement.